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Abstract
Background: Perinatal depression carries adverse effects on maternal health and
child development, but genetic underpinnings remain unclear. We investigated the
polygenic risk of perinatal depressive symptoms.
Methods: About 742 women from the prospective Prediction and Prevention of Pre‐
eclampsia and Intrauterine Growth Restriction cohort were genotyped and com-
pleted the Center for Epidemiologic Studies Depression scale 14 times during the
prenatal period and twice up to 12 months postpartum. Polygenic risk scores for
major depressive disorder, bipolar disorder, schizophrenia, and cross‐disorder were
calculated using multiple p‐value thresholds.
Results: Polygenic risk scores for major depressive disorder, schizophrenia, and
cross‐disorder, but not bipolar disorder, were associated with higher prenatal and
postpartum depressive symptoms (0.8%–1% increase per one standard deviation
increase in polygenic risk scores). Prenatal depressive symptoms accounted for and
mediated the associations between the polygenic risk scores and postpartum de-
pressive symptoms (effect size proportions‐mediated: 52.2%–88.0%). Further, the
polygenic risk scores were associated with 1.24–1.45‐fold odds to belong to the
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2020 The Authors. Depression and Anxiety published by Wiley Periodicals LLC
group displaying consistently high compared with consistently low depressive
symptoms through out the prenatal and postpartum periods.
Conclusions: Polygenic risk scores for major depressive disorder, schizophrenia, and
cross‐disorder in non‐perinatal populations generalize to perinatal depressive
symptoms and may afford to identify women for timely preventive interventions.
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1 | INTRODUCTION
Maternal perinatal depression, defined as depression during pregnancy
or within 12 months of childbirth, affects over 1 of 10 women in
childbearing age (World Health Organizaton, 2015). Reported clinically
relevant symptoms are even more common, affecting 1 of 5 women
(Kumpulainen et al., 2018; Lahti et al., 2017). It causes a major burden
on the health and well‐being of the women and is associated with
problems such as gestational diabetes and hypertension in pregnancy
(Bansil et al., 2009) and obesity (Kumpulainen et al., 2018). It is also a
major risk factor of suicide, one of the most common causes of death
among women during the perinatal period (Chang, Berg, Saltzman, &
Herndon, 2005; Nock et al., 2008). In addition to the women them-
selves, perinatal depression affects their children: prenatal depression
is associated with developmental adversities, including increased risk
of low birth weight and preterm birth (Pesonen et al., 2016). Both
prenatal and postpartum depression (PPD) are associated with lower
rates and shorter duration of breastfeeding (Figueiredo, Canário, &
Field, 2014), less secure mother‐child attachment (Martins &
Gaffan, 2000), and higher risk of child neurodevelopmental, emotional,
and behavioral problems (Lahti et al., 2017; Toffol et al., 2019;
Tuovinen et al., 2018; Wolford et al., 2017).
While the risk of perinatal depression is modified by psychosocial
(Yim, Tanner Stapleton, Guardino, Hahn‐Holbrook, & Dunkel
Schetter, 2015) and hormonal (Schiller, Meltzer‐Brody, & Rubinow, 2015)
factors, twin (Treloar, Martin, Bucholz, Madden, & Heath, 1999;
Viktorin et al., 2016), sibling (Murphy‐Eberenz et al., 2006; Viktorin
et al., 2016) and family (Forty et al., 2006; Pearson et al., 2018) studies
indicate that heritable factors also play a part. Heritability estimates of
perinatal depression have varied between 25% (Treloar et al., 1999) and
54% (Viktorin et al., 2016) in twin studies, and 44% (Viktorin
et al., 2016) in a sibling study. Furthermore, the daughters of prenatally
depressed women have over the threefold risk of depression during
their own pregnancy (Pearson et al., 2018). While perinatal depression
and nonperinatal major depressive disorder (MDD) may represent at
least partly distinct disorders, perinatal depression at least partially
shares its genetic component with MDD (Viktorin et al., 2016) and
bipolar disorder (BD; Payne et al., 2008). Moreover, the genetic com-
ponent may also be shared with schizophrenia (SCZ), anorexia nervosa,
attention‐deficit/hyperactivity disorder (ADHD), autism spectrum dis-
order (ASD), obsessive–compulsive disorder (OCD) and Tourette syn-
drome, due to the partially shared heritability between MDD and these
disorders (Lee et al., 2013; Lee et al., 2019). Furthermore, candidate
gene studies have linked single nucleotide polymorphisms (SNPs) with
the risk of these disorders. However, it is unlikely that the heritabilities
of these complex disorders are assigned to individual SNPs. Indeed, a
recent meta‐analysis concluded that no candidate genes or gene sets
reliably predict depression phenotypes (Border et al., 2019).
A promising alternative is the polygenic risk score (PRS) approach,
which exploits findings from genome‐wide association studies (GWAS)
using an aggregate measure of weighted genetic variants associated
with the phenotype. One study showed that PRSs for BD, but not MDD,
were associated with postpartum depression (Byrne et al., 2014).
However, the study used polygenic profile scoring methodology instead
of association analysis and exploited summary statistics from an older
GWAS. In addition, to our best knowledge, no PRS study has sufficiently
accounted for the other risk factors of perinatal depression and have
focused only on PPD. However, women suffering from PPD often have
elevated depressive symptoms already during early pregnancy (Evans
et al., 2012; Kumpulainen et al., 2018; Tuovinen et al., 2018; van der
Waerden et al., 2017), indicating that PPD is often a continuation of
prenatal depression.
Accordingly, we investigated PRSs based on the most recent and
largest GWAS on MDD (Howard et al., 2019; Wray et al., 2018), BD
(Ruderfer et al., 2018; Stahl et al., 2019), SCZ (Ripke, Neale, &
Spiker, 2014; Ruderfer et al., 2018) and cross‐disorder (CD; including
MDD, BD, SCZ, anorexia nervosa, ADHD, ASD, OCD, and Tourette
syndrome; Lee et al., 2019) (a) predict prenatal and postpartum de-
pressive symptoms, (b) if prenatal depressive symptoms account for,
and hence mediate, or (c) moderate the associations of the PRSs and
postpartum depressive symptoms, and (d) if these PRSs predict
fluctuating or consistently high levels of depressive symptoms
throughout the perinatal period.
2 | MATERIALS AND METHODS
2.1 | Participants
The participants come from the Prediction and Prevention of
Pre‐eclampsia and Intrauterine Growth Restriction (PREDO) study
(Girchenko et al., 2017). We enrolled 1,079 pregnant women to the
clinical subsample: 969 had one or more, and 110 had none of the
known risk factors for pre‐eclampsia and intrauterine growth restriction.
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The women were recruited on their first ultrasound screening at 12–14
gestational weeks from 10 hospitals in Southern and Eastern the 1,079
women, 997 donated blood for DNA in early pregnancy (median = 13.0;
interquartile range = 12.6–13.4 weeks). Of them, 742 (74.4%) had data
available on prenatal or postpartum depressive symptoms; these women
formed our analytic sample. Of them, data were available on prenatal
depressive symptoms for 721 (97.2%), postpartum depressive symptoms
for 726 (97.8%), and both for 705 (95.0%).
Compared with the rest of the clinical subsample, the women in the
analytic sample more often had attained tertiary education (42.7% vs.
55.0%; χ2 = 15.29; p< .001), but did not significantly differ otherwise.
2.2 | Ethics statement
All participants signed informed consent forms. The PREDO study pro-
tocol has been approved by the ethical committee of the Helsinki and
Uusimaa Hospital District, and aligns with the Declaration of Helsinki.
2.3 | Genotyping
Genotyping was performed on the IlluminaGlobal Screening array
(Illumina Inc, San Diego, CA) at the Erasmus MC, The Netherlands
and imputed with IMPUTE 2.3.2 and Eagle v2.3 against Finnish‐
specific SISu v2 reference panel (GRCh37) comprising 2690 high‐
coverage whole‐genome and 5093 high‐coverage whole‐exome
sequences, which introduces less false polymorphisms than using
global reference panels (Surakka et al., 2016). Before imputation,
variants with call rate <0.95, MAF > 0.35, minor allele count <19 or
HWE p < 1 × 10−6 were excluded. Samples were excluded based on
call rate <0.95, heterozygosity F < 0.1, sex mismatch, and relatedness.
Population outliers were excluded based on visual inspection. There
were 15,544,584 variants after imputation.
2.4 | PRS of MDD, BD, SCZ, and CD
PRS for MDD (Howard et al., 2019; Wray et al., 2018; hereafter
referred to as MDD2018 and MDD2019), BD (Ruderfer et al., 2018;
Stahl et al., 2019; BD2018 and BD2019), SCZ (Ripke et al., 2014;
Ruderfer et al., 2018; SCZ2014 and SCZ2018), and CD (Lee
et al., 2019) were calculated by taking genetic variants from the
imputed best guess genotypes up to varying significance thresholds
from the GWAS discovery sample and applying a score from these
variants, weighted by the associations in the discovery sample, to
predict a trait in an independent target sample. Clumping and
calculation of PRSs were performed using PRSice‐2 (Choi &
O'Reilly, 2019), using LD threshold (R2) 0.1 and clumping window
width of 500 kilobases. Before clumping, we excluded all SNPs with
INFO score < 0.90. Other filtering criteria in the PREDO sample in-
cluded HWE p < 1 × 10−6 and missingness > 0.05. PRSs were created
using p‐value thresholds 5 × 10−8, .001, .01, and .05. The number of
SNPs in each PRS is in Table 1. The correlations between the PRSs
are in Tables S1–S4.
2.5 | Depressive symptoms
The women completed the Center for Epidemiologic Studies
Depression Scale (CES‐D; Radloff, 1977) biweekly up to 14 times
throughout the perinatal period starting from 120/7–136/7 until
380/7–396/7 or delivery, and twice during the postpartum period
(median 2.1 weeks and 6.4 months, interquartile range 2.0–2.4 weeks
and 6.1–7.3 months, respectively). The 20 CES‐D questions were
rated on a scale from none (0) to all of the time (3). Higher scores
indicate more depressive symptoms during the past week.
2.6 | Covariates
These included age at delivery (years), family structure (cohabiting/
married vs single parent), body mass index (BMI) in early pregnancy
(kg/m2) and cigarette smoking (smoked through pregnancy/quit in
early pregnancy vs no) with data from the Medical Birth Register.
Education (secondary, tertiary vs basic) and alcohol use (yes vs no)
were reported in early pregnancy. We conducted multidimensional
scaling analyses on the whole genome genotypes with Plink v0.64 to
control for population stratification. Four main components depicted
the population substructure.
TABLE 1 Numbers of SNPs in the
polygenic risk scores
p‐Value
threshold MDD2018 MDD2019 BD2018 BD2019 SCZ2014 SCZ2018 CD
p < 5 × 10–8 48 66 8 13 118 80 134
p < .001 2100 2529 1263 1514 2892 2352 3251
p < .01 7614 9104 5618 6070 8804 7859 10190
p < .05 19404 23301 15730 16380 20129 18951 23562
Abbreviations: BD2018, bipolar disorder (Ruderfer et al., 2018); BD2019, bipolar disorder (Stahl
et al., 2019); CD, cross‐disorder; MDD2018, major depressive disorder (Wray et al., 2018);
MDD2019, major depressive disorder (Howard et al., 2019); SCZ2014, schizophrenia (Ripke
et al., 2014); SCZ2018, schizophrenia (Ruderfer et al., 2018).
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2.7 | Statistical methods
Linear regression analyses tested the associations between the PRSs
and prenatal (mean of all 14 prenatal values) and postpartum (mean
of the two postpartum values) depressive symptoms. We then tested
if the associations between the PRSs and postpartum depressive
symptoms were accounted for by prenatal depressive symptoms, by
adding prenatal depressive symptoms to the regression equations.
We pursued mediation if all variables were significantly interrelated
and the regression coefficient diminished after introducing the
mediator into the model (Baron & Kenny, 1986). To study if prenatal
depressive symptoms moderated the associations between the PRSs
and postpartum depressive symptoms, we included a prenatal de-
pressive symptoms × PRS interaction termin the regression equation
together with the main effects.
Finally, to study if the PRSs were associated with fluctuating or
persistently high levels of prenatal and postpartum depressive
symptoms, we first applied latent class analysis (LCA) to identify
subgroups of women based on their depressive symptoms levels
across all measurements. We compared two to six subgroups solu-
tions using the following criteria for the optimal solution: (a) Akaike
and Bayesian Information Criteria of goodness‐of‐fit, (b) at least 10%
of the sample in each subgroup, (c) high classification certainty
identified by posterior probabilities, (d) clinical relevance (Kongsted &
Nielsen, 2017), and (e) changes in log likelihoods for increasing the
number of subgroups. Using multinomial and ordinal regression
analyses, we then examined if the PRSs were associated with the
depressive symptoms subgroups identified as optimal.
We present the associations as adjusted for the MDS and ma-
ternal age, and further for all covariates. We normalized CES‐D va-
lues with square root transformation and standardized the CES‐D
scores and the PRSs (Mean = 0; SD = 1) to facilitate interpretation.
Unstandardized regression coefficients and odds ratios (OR) and 95%
confidence intervals (95% CI) with two‐tailed p‐values present effect
sizes.
We controlled for multiple testing with a false detection rate
(FDR) procedure (Benjamini & Hochberg, 1995). We corrected for 5%
FDR over 28 tests (seven PRSs with four p‐value thresholds), sepa-
rately for prenatal and postpartum CES‐D scores and for each sta-
tistical model.
We conducted the analyses using SPSS v24 and PROCESS macro
v3.3 (Hayes, 2017) with a custom model builder (Frank, 2018) using
10,000 bootsrapped samples. We corrected for FDR using the p.ad-
just function in R.
2.8 | Data availability statement
The data that support the findings of this study are available on
request from the corresponding author. The data are not publicly
available due to privacy or ethical restrictions.
Data requests may be subject to further review by the Finnish
national register authorities, and by the ethical committees.
3 | RESULTS
Sample characteristics are in Table 2. The CES‐D scores were cor-
related across all 16 measurements (Pearson's r = .40–.81; p < .001).
The correlation between the means of prenatal and postpartum
measurements was Pearson's r = .68 (p < .001). Of the covariates,
only alcohol use and early pregnancy BMI were correlated with
prenatal depressive symptoms (Pearson's r ≥ .09; p ≥ .022), and none
were correlated with postpartum depressive symptoms (Table S5).
3.1 | PRS and prenatal and postpartum depressive
symptoms
Table 3 shows that the MDD2018, MDD2019, SCZ2014, SCZ2018,
and CD PRSs with p‐value threshold .01 were significantly associated
with higher levels of prenatal and postpartum depressive symptoms
in both statistical models adjusting for covariates, except for
TABLE 2 Sample characteristics
Characteristic Mean (SD) or n (%)
Maternal age at delivery (years) 33.4 (5.6)
Missing data 0 (0.0%)
Education
Basic 24 (3.2%)
Secondary 299 (40.3%)
Tertiary 408 (55.0%)
Missing data 11 (1.5%)
Family structure
Married or cohabit 720 (97.0%)
Single 22 (3.0%)
Missing data 0 (0.0%)
Early pregnancy BMI (kg/m2) 27.2 (6.7)
Missing data 0 (0.0%)
Smoking during pregnancy
No 703 (94.7%)
Yes 38 (5.1%)
Missing data 1 (0.1%)
Alcohol use in early pregnancy
No 609 (82.1%)
Yes 115 (15.5%)
Missing data 18 (2.4%)
CES‐D
Prenatal mean score 11.4 (6.6)
Above clinical cutoff (≥16) 152 (20.5%)
Missing data 21 (2.8%)
Postpartum mean score 10.2 (7.3)
Above clinical cutoff (≥16) 138 (18.6%)
Missing data 16 (2.2%)
Abbreviations: BMI, body mass index; CES‐D, Center of Epidemiologic
Studies Depression Scale; SD, standard deviation.
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F IGURE 1 Mediation of the association between polygenic risk scores and postpartum depressive symptoms by prenatal depressive
symptoms. The association between polygenic risk scores of MDD2018 (a), MDD2019 (b), SCZ2014 (c), SCZ2018 (d), and CD (e), and
postpartum depressive symptoms is mediated by prenatal depressive symptoms. Thep‐values and regression coefficients shown are
for the PRSs calculated using the p‐value threshold p < .01, and adjusted for maternal age at delivery and population stratification.
p‐Values for indirect effects are from Sobel's test. PRS, polygenic risk score
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MDD2019, which was not associated with prenatal depressive
symptoms in the fully adjusted model. The associations were similar
but less consistent with the other p‐value thresholds (Table 3). The
PRSs for BD were not associated with prenatal or postpartum de-
pressive symptoms (Table S6).
The proportion of variance explained by the entire statistical
models varied between 1.3% and 6.2% for prenatal and 1.5–5.9% for
postpartum depressive symptoms; R2's of the PRSs alone are in
Table 3. To further characterize the polygenic basis of perinatal de-
pressive symptoms, we conducted stepwise linear regression analyses
where we first entered Model 1 covariates and then tested using
forward selection which of the PRSs with p‐value threshold 0.01 im-
proved model fit the most. The PRSs for SCZ2018 and SCZ2014 were
the best predictors of prenatal and postpartum depressive symptoms,
respectively, and MDD2018 significantly predicted additional variance
in prenatal and postpartum depressive symptoms: for adding the
second PRS, R2 changes were .7% and 1.0%, F's for change 5.20 and
7.14, and p = .02 and p = .008, respectively.
3.2 | PRS and prenatal and postpartum depressive
symptoms: Mediation and moderation
No PRSs were significantly associated with postpartum depressive
symptoms in models including prenatal depressive symptoms
(Table 3; Table S6). As the criteria were met (Table 3 and significant
correlations between prenatal and postpartum depressive symp-
toms), we pursued mediation tests. Prenatal depressive symptoms
mediated the associations between the PRSs for MDD2018,
MDD2019, SCZ2014, SCZ2018, and CD and postpartum depressive
symptoms (effect size proportions mediated varied between 52.2%
and 88.0%; Figure 1). After accounting for mediation, the direct ef-
fects of the PRSs for MDD2018, SCZ2014, and SCZ2018 remained
significant, but MDD2019 and CD did not (Figure 1).
Analyses testing if prenatal depressive symptoms moderated the
associations between the PRSs and postpartum depressive symptoms
revealed no significant interactions (prenatal depressive symp-
toms × PRS interactions p ≥ .152; data not shown).
F IGURE 1 (Continued)
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3.3 | PRS and prenatal and postpartum depressive
symptoms: Fluctuating or persistently high level of
symptomatology
In the LCA we compared two to six subgroups solutions, and based
on the five criteria identified a solution with three latent classes as
optimal (Table S7). Each of the three subgroups showed high de-
pressive symptom stability throughout the prenatal and postpartum
periods (Figure 2). The groups differed in symptom severity, showing
consistently low (n = 158; 21.3%), moderate (n = 397; 53.5%) and
high, clinically significant (CES‐D scores ≥ 16; Radloff, 1977; n = 187;
25.2%) levels of depressive symptoms.
Figure 3 shows that for each SD increase in the PRSs for
MDD2018, MDD2019, SCZ2014, SCZ2018, and CD with p‐value
threshold .01 and for each SD increase in PRSs for MDD2018,
SCZ2018, and CD with p‐value threshold .05, the odds to belong to
the group with consistently high compared with low depressive
symptoms throughout the prenatal and postpartum periods were
significantly higher (OR = 1.24–1.45). The PRSs for CD and
SCZ2014 at 0.01 and 0.05 p‐value thresholds were also associated
with significantly higher odds (OR = 1.23–1.29) to belong to the
group with consistently moderate compared with low depressive
symptoms (Figure 3). The odds to belong to the LCA subgroups
with consistently low, moderate, and high levels of depressive
symptoms increased linearly with higher values of the PRSs
(Figure 3). Figure 3 also shows the means of the PRSs according to
the LCA subgroups.
The PRSs for BD2018 and BD2019 were not significantly asso-
ciated with the LCA subgroups.
4 | DISCUSSION
We found that the PRSs for MDD2018, MDD2019, SCZ2014, and
SCZ2018 and CD, but not BD2018 or BD2019, predicted higher
levels of prenatal and postpartum depressive symptoms. While all the
PRSs were correlated, only MDD2018, SCZ2014, and SCZ2018 sig-
nificantly predicted unique variance in depressive symptoms. The
associations were significant across PRSs calculated using multiple
p‐value thresholds, but they were most consistent with the PRSs
containing larger numbers of SNPs. This is likely related to the ge-
netic variance reflected in the different PRSs, as the numbers of
SNPs differ widely between different p‐value thresholds (Table 1).
These findings thus suggest that the genetic risk of MDD, SCZ, and
CD in nonperinatal populations may generalize to depressive symp-
toms in perinatal women.
The effect sizes that predicted prenatal and postpartum de-
pressive symptoms were small, but of similar magnitude as those of
the covariates (Table S5). Moreover, as previously reported (Evans
et al., 2012; Kumpulainen et al., 2018; Tuovinen et al., 2018; van der
Waerden et al., 2017), the best predictor of postpartum depressive
symptomatology was prenatal symptomatology.
However, the effect size estimates were much larger when we
took into account the high stability of depressive symptoms
throughout the perinatal period. Our LCA indicated that the PRSs for
MDD2018, MDD2019, SCZ2014, SCZ2018, and CD were associated
with a trajectory of consistently high depressive symptoms across
the perinatal period; one SD increase in these PRSs translated to
1.24–1.45 increase in the odds to belong to the group with con-
sistently high compared with low depressive symptoms. Thus, genetic
F IGURE 2 Latent profiles of maternal prenatal and postpartum depressive symptoms. The figure shows the mean levels of depressive
symptoms in the three classes derived from latent class analysis of women who showed consistently low, consistently moderate and
consistently high levels of depressive symptoms throughout pregnancy and up to 12 months after delivery. Error bars represent
95% CI's
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F IGURE 3 Polygenic risk for MDD2018, MDD2019, SCZ2014, SCZ2018, and CD by the three latent class analysis subgroups of
perinatal depressive symptoms. PRSs for MDD2018 (a), MDD2019 (b), SCZ2014 (c), SCZ2018 (d), and CD (e) calculated using p‐value
thresholds .01 and .05 by the three latent class analysis subgroups of women with consistently low, consistently moderate and
consistently high levels of depressive symptoms throughout pregnancy and up to 12 months after delivery. Error bars represent 95%
CI's. Odds ratios for subgroup membership and linear trends across subgroups are adjusted for maternal age at delivery and population
stratification. PRS, polygenic risk score
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F IGURE 3 (Continued)
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vulnerability may be present in a larger proportion of women suf-
fering from consistently high levels of depressive symptoms
throughout the perinatal period.
Because of this high correlation between prenatal and post-
partum depressive symptomatology, the associations between the
PRSs and postpartum symptomatology were rendered nonsignificant
when prenatal symptomatology was introduced into the model. In-
deed, the associations with postpartum depressive symptoms were
mediated by prenatal depressive symptoms. However, as the effect
size proportions mediated were 52.2%–88.0% for the different PRSs,
other mediating factors may also play a role. Interactions between
the PRSs and prenatal depressive symptoms were not significantly
associated with postpartum depressive symptoms. Thus, the genetic
risk of prenatal depressive symptoms accounted for and did not
moderate the genetic risk of postpartum depressive symptoms. This
finding reflects that depressive symptoms were highly stable
throughout the perinatal period.
One previous study has investigated the associations between
PRSs for MDD and BD and depression during the perinatal period
(Byrne et al., 2014). In this study the PRS for BD, but not MDD, was
associated with PPD. Our findings are discrepant with this study;
there are several possible explanations. First, the earlier study fo-
cused on PPD instead of the entire perinatal period. Second, our
study used different depression outcomes. While we used depressive
symptoms as a continuous variable measured with a questionnaire,
the prior study predicted case/control status measured using
methods including questionnaires, retrospective reports and clinical
interviews in the studied cohortsIndeed, the authors noted that
differences in case ascertainment methods may have influenced their
findings. Third, the discrepancy may be related to differences in the
measures of polygenic risk between our studies. The earlier study
used polygenic profile scores (Purcell et al., 2009), and used risk
scores for MDD and BD from different discovery samples than ours.
Fourth, ethnic differences may explain the discrepancies, as our
study was conducted in a homogenous Finnish cohort, and the prior
study combined British, Dutch, Swedish, and Australian samples
(Byrne et al., 2014).
Recent studies have investigated the polygenic prediction of
MDD (Halldorsdottir et al., 2019; Musliner et al., 2019) and BD and
SCZ (Musliner et al., 2019) using PRSs calculated using the same
GWAS summary statistics as we did (Ripke et al., 2014;
Ruderfer et al., 2018; Wray et al., 2018). While these studies were
conducted outside the perinatal period, they are relevant due to the
partially shared genetic component among the different disorders
(Cross‐Disorder Group of the Psychiatric Genomics et al., 2013; Lee
et al., 2019; Viktorin et al., 2016), risk factors and biological me-
chanisms of vulnerability (Roy & Campbell, 2013; Schiller et al, 2015;
Serati, Redaelli, Buoli, & Altamura, 2016; Yim et al., 2015). These
studies found that PRSs for MDD2018 predicted the risk of MDD in
adolescents (Halldorsdottir et al., 2019) and MDD2018, SCZ2014
and BD2018 predicted the risk of MDD in children and adults
(Musliner et al., 2019), though the PRS for BD2018 predicted the
F IGURE 3 (Continued)
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smallest increases in hazard ratios. These findings partially agree with
and partially conflict with ours, though our study differs in depression
phenotype and age, and was restricted to perinatal women. Ethnic
differences may also explain why the PRSs for BD were not asso-
ciated with depressive symptoms in our study. Alternatively, since the
PRS for BD2018 predicted smaller increases in hazard ratios for than
MDD2018 and SCZ2014 in the previous study (Musliner et al., 2019),
it is possible that significant associations could be found in samples
larger than ours. While our findings provide important evidence of the
shared genetic components between perinatal depression and other
psychiatric disorders, further studies are warranted to elucidate the
relationships between their respective genetic bases.
The strengths of this study include prospective design, multiple
measurements of depressive symptoms during pregnancy and after
delivery, and a well‐characterized sample with data available on
multiple important covariates. Also, as most of the genotyped samples
had data on depressive symptoms available during pregnancy and
after delivery, sample attrition is unlikely to have influenced our
findings. The limitations include the lack of measurement of depres-
sive symptoms before pregnancy, and relatively modest statistical
power to detect genetic effects. Also, the comparability of our find-
ings to studies using diagnoses of depressive disorders and conducted
in populations with different characteristics and ethnicities is limited.
Furthermore, our PRSs do not account for gene–environment inter-
actions, as they were based on summary statistics from GWASs in-
vestigating main effects.
5 | CONCLUSIONS
We found that two different PRSs for MDD and SCZ and PRS for CD,
but not two PRSs for BD, were associated with prenatal and post-
partum depressive symptoms. We also found that the associations
between the PRSs and postpartum symptomatology were accounted
for, and hence mediated prenatal depressive symptoms and that the
PRSs predicted persistently high depressive symptoms throughout
the perinatal period. Our study is consistent with the earlier findings
suggesting that perinatal and nonperinatal depressive symptoms
(Viktorin et al., 2016), and MDD (Viktorin et al., 2016), and SCZ
(Cross‐Disorder Group of the Psychiatric Genomics et al., 2013; Lee
et al., 2019) in non‐perinatal populations, have a partially shared
genetic basis, and suggests that PRSs for MDD, SCZ, and CD may
afford to identify women at increased risk of perinatal depression for
timely preventive interventions.
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